Intended for healthcare professionals


Rheumatoid arthritis: NICE recommends more treatments for patients with moderate disease

BMJ 2021; 373 doi: (Published 11 June 2021) Cite this as: BMJ 2021;373:n1485
  1. Jacqui Wise
  1. Tenterden, UK

Doctors can now prescribe the biological treatments adalimumab, etanercept, and infliximab for patients with moderate rheumatoid arthritis who have not responded to conventional therapies, following updated guidance from the National Institute for Health and Care Excellence (NICE).1 Biological treatments were previously recommended only for patients with severe rheumatoid arthritis.2

NICE reviewed the evidence again because of the availability of biosimilar versions of adalimumab and etanercept and changes in the prices for …

View Full Text

Log in

Log in through your institution


* For online subscription